• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

UCLA forms collaboration with Yuyu Pharma to develop drug for stroke recovery
UCLA has formed a research collaboration with South Korea-based Yuyu Pharma to develop drugs that could help people recover after a stroke.Yuyu will develop drug candidates and UCLA researchers will conduct preclinical trials that could lead to further development of new compounds.Leading the research for UCLA are Istvan Mody, a distinguished professor of neurology; Varghese John, a professor of neurology and the principal investigator at theDrug Discovery Lab at UCLA; and Dr. S. Thomas Carmichael, chair of the UCLA department of neurology.There is currently no medical therapy that promotes recovery in the brain after it h...
Source: UCLA Newsroom: Health Sciences - March 16, 2021 Category: Universities & Medical Training Source Type: news

New Partnership Forms to Develop Breakthrough Neuromodulation Device
WeHealth, an e-health department of Servier Group, said it is in a partnership with Pathmaker Neurosystems, a pioneering clinical-stage bioelectronic medicine company. The two companies revealed plans to develop and commercialize the first neuromodulation technology designed to treat muscle spasticity non-invasively. The new technology will be known as the MyoRegulator device. The new MyoRegulator PM-200 provides a non-invasive treatment option for patients suffering from muscle spasticity, a common condition found in many patients suffering from stroke, cerebral palsy, multiple sclerosis, spinal cord injury, and traumatic...
Source: MDDI - March 26, 2019 Category: Medical Devices Authors: Kristopher Sturgis Tags: Business Source Type: news

The ms-smart trial in secondary progressive multiple sclerosis: a multi-arm, multi-centre trial of neuroprotection
There is currently no treatment for secondary progressive multiple sclerosis (SPMS) which determines the majority of disability in multiple sclerosis. The MS-SMART trial is a multi-arm, multi-centre, phase 2 randomised trial for patients with SPMS. A total of 440 patients with progressing SPMS will be recruited in England and Scotland and randomised to one of 4 blinded arms: amiloride 5mg bd, riluzole 50mg bd, fluoxetine 20mg bd or placebo. These agents have been chosen after an extensive systematic review which has suggested putative neuroprotective properties. Patients will be followed up for 96 weeks with outcome data c...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Chataway, J., Chandran, S., Miller, D., Giovannoni, G., Wheeler-Kingshott, C., Pavitt, S., Stallard, N., Hawkins, C., Sharrack, B., for the MS-SMART trialists Tags: Immunology (including allergy), Multiple sclerosis, Stroke, Radiology, Radiology (diagnostics) Thur 21, Parallel session 5: Therapeutics Source Type: research

Tau Imaging Among Breakthroughs Advancing the Fight against Alzheimer ' s
Worldwide,  nearly44 million  people now have Alzheimer ' s disease (AD) or related dementia, making these conditions the  top cause of disabilities in later life. The biopharma industry has invested billions of dollars into research to treat and prevent AD1, yet this work has faced many obstacles, including difficulty identifying biomarkers, tracking the disease ’s progress in the brain, and recruiting patients to trials while they are still asymptomatic. But in recent years, we’ve begun to see breakthroughs that is driving our research in new directions. Many of these accomplishments were highlighted at the Alzh...
Source: EyeForPharma - September 21, 2016 Category: Pharmaceuticals Authors: Olga Uspenskaya-Cadoz Source Type: news

The ms-smart trial in secondary progressive ms - current update
MS-SMART is an ongoing multicentre, multi-arm, double blind, placebo-controlled phase IIb randomised controlled trial to establish whether putative neuroprotective drugs (fluoxetine,riluzole,amiloride or placebo) can slow down the progression of brain volume loss in secondary progressive multiple sclerosis (SPMS) over 96 weeks using MRI-derived Percentage Brain Volume Change (PBVC) as the primary outcome. 360 patients have been screened so far, 328 (92%) consented and 272 randomized (65% of the total UK cohort–440). Patients will have outcome-data collected after 0,24,48 and 96 weeks. The trial is using a range of co...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Chataway, J., Chandran, S., Miller, D., Connick, P., Giovannoni, G., Pavitt, S., Stallard, N., Hawkins, C., Sharrack, B., Plantone, D. Tags: Immunology (including allergy), Multiple sclerosis, Stroke, Radiology, Radiology (diagnostics) ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

AAPT Diagnostic Criteria for Central Neuropathic Pain
Central neuropathic pain, which is pain caused by a lesion or disease of the central somatosensory nervous system, is a serious consequence of spinal cord injury, stroke, multiple sclerosis and other conditions affecting the central nervous system. A collaborative effort between the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership and the American Pain Society (APS), the ACTTION-APS Pain Taxonomy (AAPT) initiative, invited a working group to develop diagnostic criteria for central neuropathic pain.
Source: The Journal of Pain - June 27, 2017 Category: Materials Science Authors: Eva Widerstrom-Noga, John D. Loeser, Troels Staehelin Jensen, Nanna Brix Finnerup Source Type: research